Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Quantumzyme Corp. from 31 Oct 2015 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Quantumzyme Corp. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Oct 2015 to 31 Oct 2025.
  • Quantumzyme Corp. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Oct 2025 was $49,868, a 24% increase year-over-year.
  • Quantumzyme Corp. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $199,269, a 12% decline from 2024.
  • Quantumzyme Corp. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $178,569.
  • Quantumzyme Corp. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2018 was $28,167, a 27% increase from 2017.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Quantumzyme Corp. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $49,868 +$15,655 +24% 01 Aug 2025 31 Oct 2025 10-Q 15 Dec 2025 2026 Q1
Q1 2025 $65,763 -$1,901 -3% 01 Feb 2025 30 Apr 2025 10-Q 20 Jun 2025 2025 Q3
Q3 2024 $65,523 01 Aug 2024 31 Oct 2024 10-Q 15 Dec 2025 2026 Q1
Q1 2024 $63,862 01 Feb 2024 30 Apr 2024 10-Q 20 Jun 2025 2025 Q3
Q2 2018 $28,167 $25,475 -$26,023 -4749% 01 May 2018 31 Jul 2018 10-K 20 Nov 2018 2018 FY
Q1 2018 $2,144 $191 -$11,537 -98% 01 Feb 2018 30 Apr 2018 10-Q 08 May 2018 2018 Q3
Q4 2017 $9,393 $419 +$17,101 +98% 01 Nov 2017 31 Jan 2018 10-Q 13 Mar 2018 2018 Q2
Q3 2017 $7,708 $2,464 +$30,949 +93% 01 Aug 2017 31 Oct 2017 10-Q 18 Dec 2017 2018 Q1
Q2 2017 $38,657 $548 +$916 01 May 2017 31 Jul 2017 10-K 20 Nov 2018 2018 FY
Q1 2017 $39,573 $11,728 +$11,783 01 Feb 2017 30 Apr 2017 10-Q 08 May 2018 2018 Q3
Q4 2016 $51,356 $17,520 -$15,721 -874% 01 Nov 2016 31 Jan 2017 10-Q 13 Mar 2018 2018 Q2
Q3 2016 $35,635 $33,413 -$31,232 -1432% 01 Aug 2016 31 Oct 2016 10-Q 18 Dec 2017 2018 Q1
Q2 2016 $4,403 $368 01 May 2016 31 Jul 2016 10-K 19 Sep 2017 2017 FY
Q1 2016 $55 01 Feb 2016 30 Apr 2016 10-Q 13 Jun 2017 2017 Q3
Q4 2015 $1,799 01 Nov 2015 31 Jan 2016 10-Q 20 Mar 2017 2017 Q2
Q3 2015 $2,181 01 Aug 2015 31 Oct 2015 10-Q 12 Dec 2016 2017 Q1

Quantumzyme Corp. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $199,269 -$20,700 -12% 01 Aug 2024 31 Jul 2025 10-K/A 17 Nov 2025 2025 FY
2024 $178,569 01 Aug 2023 31 Jul 2024 10-K/A 17 Nov 2025 2025 FY
2018 $28,167 +$10,490 +27% 01 Aug 2017 31 Jul 2018 10-K 20 Nov 2018 2018 FY
2017 $38,657 -$34,254 -778% 01 Aug 2016 31 Jul 2017 10-K 20 Nov 2018 2018 FY
2016 $4,403 01 Aug 2015 31 Jul 2016 10-K 19 Sep 2017 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.